CJC-1295 no DAC

Compound identifiers & literature

Public database identifiers and a selection of peer-reviewed publications for CJC-1295 no DAC (Mod GRF 1-29), provided so researchers can verify this compound independently. Each entry links to the primary source.

Selected literature

1. [1]
   Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology 146(7):3052-8.

   Three maleimido derivatives of hGRF(1-29) were synthesized and conjugated ex vivo to human serum albumin; the conjugates were assessed in vitro for stability against dipeptidylpeptidase-IV and for activity in a growth hormone secretion assay in cultured rat anterior pituitary cells, and the derivatives were administered subcutaneously to normal male Sprague Dawley rats with plasma growth hormone measured. CJC-1295, described in the paper as a tetrasubstituted hGRF(1-29) bearing an N-epsilon-3-maleimidopropionamide lysine at the C terminus, gave the largest 2-hour growth hormone area under the curve and was selected for pharmacokinetic evaluation, in which it was detected in plasma beyond 72 hours.

   rodent (in vivo rat dosing, with supporting in vitro assays in cultured rat pituitary cells)PMID 15817669DOI
2. [2]
   Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology & Metabolism 91(3):799-805.

   Two randomized, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy subjects aged 21-61 years measured peak concentrations and area under the curve of plasma growth hormone and IGF-I, pharmacokinetic parameters, and adverse events following subcutaneous administration of the albumin-binding (DAC-conjugated) form of CJC-1295, given as ascending single doses in the first study and as weekly or biweekly repeated doses in the second.

   human clinical trialPMID 16352683DOI
3. [3]
   Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse American Journal of Physiology - Endocrinology and Metabolism 291(6):E1290-4.

   Three groups of one-week-old GHRH-knockout mice were treated for five weeks with 2 micrograms of the albumin-binding form of CJC-1295 at 24-, 48- or 72-hour intervals, with placebo-treated knockout mice and mice heterozygous for the knockout allele as controls. Endpoints measured were body weight and length, femur and tibia length, relative lean mass and subcutaneous fat mass, and total pituitary RNA and growth hormone mRNA, with somatotroph proliferation assessed by immunohistochemistry.

   rodentPMID 16822960DOI
4. [4]
   Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog The Journal of Clinical Endocrinology & Metabolism 91(12):4792-7.

   Healthy men aged 20 to 40 years underwent 20-minute-interval blood sampling over an overnight 12-hour period before and one week after a single injection of 60 or 90 micrograms per kilogram of the albumin-binding (DAC-conjugated) form of CJC-1295. The frequency and magnitude of growth hormone secretory pulses were reported as unaltered, while basal (trough) growth hormone levels, mean growth hormone levels and IGF-I levels were higher after administration; IGF-I changes did not correlate with any measured parameter of growth hormone secretion.

   human clinical trialPMID 17018654DOI
5. [5]
   Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation Drug Testing and Analysis 2(11-12):647-50.

   An unknown pharmaceutical preparation submitted in 2009 by Norwegian police and customs authorities was analysed by liquid chromatography-high resolution tandem mass spectrometry and found to contain a 29-amino-acid peptide with a C-terminal amide function; a sequence was proposed from the mass spectrometric data and reported as consistent with the peptide marketed under the name CJC-1295. No cell, tissue or animal experiment was performed. The paper states that CJC-1295 is a releasing factor for growth hormone and is therefore considered a Prohibited Substance under Section S2 of the WADA Prohibited List.

   analytical chemistry - no biological model (not in vitro, not animal, not human)PMID 21204297DOI

These references are provided for scientific context only. They describe published research on this compound and are not evidence of safety or efficacy, not an endorsement of any use, and not medical advice. This product is supplied for laboratory research use only — not for human or animal consumption.